Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

Slides:



Advertisements
Similar presentations
Risk Communication Advisory Committee Risk Communication Issues in the Food and Drug Administration Amendments Act of 2007 February 28, 2008.
Advertisements

SUBPART D PRESENTATION Inaugural meeting of the Pediatric Ethics Subcommittee (PES) of the Pediatric Advisory Committee (PAC); part of the inaugural meeting.
Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.
FDA Perspective Sally Loewke, M.D. Acting Division Director
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Clinical Trials Registry Susan Koenig, MPP&PA Director, Office of Compliance & Quality University of Missouri-Columbia School of Medicine Compliance &
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
CBER Managed Review Process Sheryl A. Kochman Deputy Director, DBA, OBRR, CBER September 15, 2009.
Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
The Risks of Cough/Cold Preparations to Young Children Michael Shannon, MD, MPH Children’s Hospital Boston Harvard Medical School.
11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
The National Vaccine Plan Process - Update October 22, 2007 Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human Services.
Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.
1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.
FDA/DDC Meeting Lynda Dee July 28, 2008 July 28, 2008.
Overview of Research Oversight: U.S. Perspective Leslie K. Ball, M.D., F.A.A.P. Office for Human Research Protections Department of Health and Human Services.
Investigational New Drug Application (IND)
Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.
Pediatric Advisory Committee Meeting September 15, 2004
Draft Model Manufacturer Agreement Medicare Coverage Gap Discount Program Public Meeting June 1, 2010.
1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.
Status of SACHRP Recommendations July 2003-October 2008 Meeting of the Secretary’s Advisory Committee on Human Research Protections October 27, 2008 Michael.
1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.
1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
History of Pediatric Labeling
CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005.
1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
FDAAA – Report on DTC Advertising Kristin Davis, J.D. Deputy Director, Division of Drug Marketing, Advertising, and Communications Office of Medical Policy,
FDA Regulatory and Compliance Symposium
FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.
Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.
February 2, 2004 Pediatric Drug Development: A Decade of Progress: Susan K. Cummins, MD, MPH Medical Team Leader Division of Pediatric Drug Development.
July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.
1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.
Initiatives Drive Pediatric Drug Development January 30, 2002.
1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.
1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.
Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.
1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.
1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.
Dr. Dianne Murphy, M.D. Associate Director of Pediatrics September 12, 2000 Center for Drug Evaluation and Research Food and Drug Administration.
Regulation of Generic Animal Drugs in the United States
1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.
Dailymed/RxNorm Jamboree Leyla Rahjou-Esfandiary September 2016
PAEDIATRIC REGULATION
Pre-Investigational New Drug (pre-IND) Meeting with FDA
Formal Meetings between FDA and Sponsors of PDUFA Products
SPL Implementation Working Group Leyla Rahjou-Esfandiary October 2016
CLINICAL TRIAL REGISTRIES
Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.
Pediatric Clinical investigator training workshop
Opening an IND: Investigator Perspective
USP’s Model Guidelines for the Medicare Drug Benefit
Community Investment Grant
Pediatric Therapeutics Still working to get it right for kids
Presentation transcript:

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November 16 th, 2006

Section 17 : The Best Pharmaceuticals for Children Act Drugs with Pediatric Market Exclusivity Drugs with Pediatric Market Exclusivity (1) In General.-During the 1-year beginning on the date on which a drug receives a period of market exclusivity under 505A Of the FD&C Act, any report of an adverse event regarding the drug that the Secretary of HHS receives shall be referred to the Office of Pediatric Therapeutics. In considering the report, the Director of such Office shall provide the review of the report by the PAC, including obtaining any recommendations of such Committee regarding whether the Secretary should take action under the FD&C Act in response to the report.

Section 5: BPCA Timely Labeling Changes for Drugs Granted Exclusivity (2) Dispute Resolution (2) Dispute Resolution (A) Request for Labeling Change and Failure to Agree.- (A) Request for Labeling Change and Failure to Agree.- Basically, if labeling is the only open issue for final action, no later than 180 days after submission of the application- (ii) if the sponsor of the application does not agree to make the labeling change requested by the Commissioner, the Commissioner shall refer the matter to the PAC. The PAC has 90 days to review and make recommendations. (ii) if the sponsor of the application does not agree to make the labeling change requested by the Commissioner, the Commissioner shall refer the matter to the PAC. The PAC has 90 days to review and make recommendations. We have not had to use this Section of the BPCA though we have told sponsors we were going this route and resolution was reached.

Evolution of Process DATABASE ISSUES: DATABASE ISSUES: -Dr. Rosemary Johann-Liang will be reviewing for you the limitations and strengths of AERS and other databases available to FDA; there have been some changes -We have no Active Surveillance pediatric program for AE’s related to drugs; there are limited data in this area -The PAC has expressed the need for a denominator and better context in relation to the reporting of adverse events REPORTING PRACTICES: REPORTING PRACTICES: -The PAC has stated they do not need to see all AE’s but definitely wanted to see all deaths and serious adverse events

Response to Requests of PAC Reviews no longer concentrate on the top 20 adverse events. Reviews no longer concentrate on the top 20 adverse events. Reviews do focus on deaths and serious AE’s. If required to provide a better understanding of what is happening, AE’s not only from the 1 year post exclusivity but from all years since marketing are presented. This includes integration of knowledge about what is occurring with adults when this information is thought to be relevant. Reviews do focus on deaths and serious AE’s. If required to provide a better understanding of what is happening, AE’s not only from the 1 year post exclusivity but from all years since marketing are presented. This includes integration of knowledge about what is occurring with adults when this information is thought to be relevant.

Response to PAC The pediatric trials conducted for pediatric exclusivity are provided to and reviewed for the PAC. This is an effort to provide the context of safety reporting during a controlled trial and to provide information on possible benefit(s) to be derived from use of the product. The pediatric trials conducted for pediatric exclusivity are provided to and reviewed for the PAC. This is an effort to provide the context of safety reporting during a controlled trial and to provide information on possible benefit(s) to be derived from use of the product.

Response to PAC Presentations are classified in 3 ways to permit focusing on the more interesting or controversial products. Presentations are classified in 3 ways to permit focusing on the more interesting or controversial products. Abbreviated, Standard & In-depth Committee receives the same complete package for all new exclusivity products, irrespective of the type of presentation. Committee receives the same complete package for all new exclusivity products, irrespective of the type of presentation. Follow-up reviews are provided in response to the Committee’s request Follow-up reviews are provided in response to the Committee’s request

1-Year Post Pediatric Exclusivity Safety Reviews Status - to 11/06 Dates: June November 2006 # of PAC meetings: 10 # of PAC meetings: 10 # of 1 st time Reviewed Drugs Total: 65 # of 1 st time Reviewed Drugs Total: 65 # of Committee Requested Follow-ups: 6 # of Committee Requested Follow-ups: 6 In-depth/Full PAC Reviews: 9 In-depth/Full PAC Reviews: 9 Drug Categories: 15 Drug Categories: 15 Drug Usage Estimates: Widely variable Drug Usage Estimates: Widely variable

Drug Categories: No./group GI: gastric; I: immunologic; R: reproductive; Rh: rheumatologic; H: hematologic; Pa: pain; U: urologic; N: neurologic; O: ophthalmologic; AP: allergy/pulmonary M: metabolic; AM: anti-microbial; P: psychiatric; CR: cardiorenal; Oc: oncologic

Today’s Activities Largest number of products (16) we have ever tried to review in one meeting. Largest number of products (16) we have ever tried to review in one meeting. There are 11 new exclusivity products and 5 PAC requested product updates. There are 11 new exclusivity products and 5 PAC requested product updates. 8 of the products will have Abbreviated presentations; the Committee receives the exact same complete package for all new products irrespective of the presentation. 8 of the products will have Abbreviated presentations; the Committee receives the exact same complete package for all new products irrespective of the presentation. Some products are in the midst of active reviews and the approach the agency is taking is being provided. For these we are providing information more than asking a question. Some products are in the midst of active reviews and the approach the agency is taking is being provided. For these we are providing information more than asking a question. Some products will have completed reviews and the Agency will be asking if the Committee is in agreement with returning these products to routine review. Some products will have completed reviews and the Agency will be asking if the Committee is in agreement with returning these products to routine review.